Known targets — ChEMBL curated mechanism
ATP1A1ATP1A2ATP1A3ATP1A4ATP1B1ATP1B2ATP1B3FXYD2
The experimentally established mechanism targets of Digoxin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 known ✓ | P05023 | 15/20 | 1.00 |
| ▸ | ATP1B1 known ✓ | P05026 | 15/20 | 1.00 |
| ▸ | ATP1B2 known ✓ | P14415 | 15/20 | 1.00 |
| ▸ | ATP1A2 known ✓ | P50993 | 15/20 | 1.00 |
| ▸ | ATP1B3 known ✓ | P54709 | 15/20 | 1.00 |
| ▸ | ATP1A3 known ✓ | P13637 | 3/20 | 1.00 |
| ▸ | FXYD2 known ✓ | P54710 | 3/20 | 1.00 |
| ▸ | ATP1A4 known ✓ | Q13733 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | STAT3 | P40763 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | RORC | P51449 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 1.00 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Digoxin SCHEMBL16341971 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL15959376 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL13496260 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL20506 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL13337586 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL13354340 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL12841137 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL16144399 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL8200838 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 | |
| Digoxin SCHEMBL22904197 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1B2ATP1A2ATP1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3182979-B1 | NOVEL COMPOSITIONS AND METHODS USEFUL FOR TREATING OR PREVENTING LIVER DISEASES OR DISORDERS, AND PROMOTING WEIGHT LOSS | UNIV YALE (US) | 2023-12-06 | — | — | EP | disclosed |
| US-10624917-B2 | Compositions and methods useful for treating or preventing liver diseases or disorders, and promoting weight loss | YALE UNIVERSITY (US) | 2020-04-21 | — | — | US | disclosed |
| US-20170232027-A1 | NOVEL COMPOSITIONS AND METHODS USEFUL FOR TREATING OR PREVENTING LIVER DISEASES OR DISORDERS, AND PROMOTING WEIGHT LOSS | UNIV YALE (US) | 2017-08-17 | — | — | US | disclosed |
| US-9585380-B2 | SSAT mRNA translation repression and activation | Temple University—Of the Commonwealth System of Higher Education (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160331771-A1 | Treatment of Hyperproliferative Disorders Using Cardiac Glycosides | COMGENRX, INC. | 2016-11-17 | — | — | US | disclosed |
| EP-2414543-B1 | GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE | DECODE GENETICS EHF (IS) | 2016-10-12 | — | — | EP | disclosed |
| US-20140234827-A1 | SSAT mRNA TRANSLATION REPRESSION AND ACTIVATION | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2014-08-21 | — | — | US | disclosed |
| US-8795963-B2 | Genetic markers for risk management of atrial fibrillation and stroke | DECODE GENETICS EHF. (IS) | 2014-08-05 | — | — | US | disclosed |
| US-8791079-B2 | Methods for treating heart failure by inhibiting the mitochondrial sodium-calcium exchanger (mNCE) | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-07-29 | — | — | US | disclosed |
| US-20120077763-A1 | METHODS FOR TREATING HEART FAILURE BY INHIBITING THE MITOCHONDRIAL SODIUM-CALCIUM EXCHANGER (mNCE) | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120021989-A1 | GENETIC MARKERS FOR RISK MANAGEMENT OF ATRIAL FIBRILLATION AND STROKE | DECODE GENETICS EHF. (IS) | 2012-01-26 | — | — | US | disclosed |
| US-20110250297-A1 | Treatment of Hyperproliferative Disorders Using Cardiac Glycosides | EPICENTRX, INC. | 2011-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077763-A1 | METHODS FOR TREATING HEART FAILURE BY INHIBITING THE MITOCHONDRIAL SODIUM-CALCIUM EXCHANGER (mNCE) | SLC8B1, ATP2A1, ATP2A2 | ATP1A1 109/4885ATP1B1 166/4885ATP1B2 87/4885 |
| US-20140234827-A1 | SSAT mRNA TRANSLATION REPRESSION AND ACTIVATION | RNMT, RNGTT, SRM | ATP1A1 1196/4885ATP1B1 1166/4885ATP1B2 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.